NCT05711719: Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction |
|
|
| Recruiting | 2 | 45 | US | Vericiguat, Verquvo, Placebo | Johns Hopkins University, Merck Sharp & Dohme LLC | Metabolic Syndrome, Coronary Microvascular Dysfunction | 06/25 | 12/25 | | |
NCT04998877: Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients |
|
|
| Recruiting | N/A | 60 | US | | Johns Hopkins University, Pfizer | Heart Failure With Preserved Ejection Fraction | 12/24 | 03/25 | | |